Chao Gao1,2,3, MD; Rutao Wang1,2,3, MD; Faisal Sharif3, MD; Kuniaki Takahashi4, MD; Masafumi Ono3,4, MD; Hironori Hara3,4, MD; Mariusz Tomaniak5, MD; Hideyuki Kawashima3,4, MD; Rodrigo Modolo6, MD; Robert-Jan M. van Geuns2, MD, PhD; Davide Capodanno7, MD, PhD; Robert A. Byrne8, MD, PhD; William Wijns3, MD, PhD; Yoshinobu Onuma3, MD, PhD; Patrick W. Serruys3,9, MD, PhD
1. Department of Cardiology. Xijing hospital, Xi’an, China; 2. Department of Cardiology, Radboud University, Nijmegen, the Netherlands; 3. Department of Cardiology, National University of Ireland Galway, Galway, Ireland; 4. Department of Cardiology, Amsterdam University Medical Center, Amsterdam, the Netherlands; 5. Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands; 6. Department of Internal Medicine. Cardiology division. University of Campinas (UNICAMP), Campinas, SP, Brazil; 7. Division of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy; 8. Deutsches Herzzentrum München, Technische Universität München, Munich, Germany; 9. NHLI, Imperial College London, London, United Kingdom, United Kingdom
Antiplatelet therapy was first introduced almost 30 years ago and remains the cornerstone of percutaneous coronary interventions (PCI). During 2019, the results of several pivotal trials seemed to herald a new era of antiplatelet therapy – the era of the aspirin-free strategy. Also in 2019, the debates on the optimal revascularisation strategy for patients with left main or multivessel disease were reignited, attempting to reduce microvascular obstruction after coronary reperfusion by early infusion of alteplase was disproven, and the result of the ISCHEMIA trial showed no advantage of routine invasive treatment in patients with chronic coronary syndrome (CCS).